Study Title
A Phase I Clinical Study Evaluating the Safety of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-DOTA0-Tyr3-Octreotate in Children With Refractory or Recurrent Neuroblastoma Expressing Somatostatin Receptors.
Study Details
Description:
This study is a multicenter, open label phase I dose escalation trial designed to define the Maximum Tolerated Dose (MTD) of 177Lu-DOTATATE in children with refractory or recurrent neuroblastoma. 177Lu-DOTATATE will be delivered intravenously for 2 cycles, 6 weeks apart. The duration of study participation of each patient will be 5 months.
Sponsor:
Institut Claudius Regaud
Contacts:
Frédéric COURBONcourbon.frederic@iuct-oncopole.fr
+33 5 31 15 55 26
Government Study Link:
NCT03966651 - Click here to see study onClinicalTrials.gov